Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868751 · ClinicalTrials.gov registry record · NA
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
A NA study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00868751: Clinical Trial NA study, sponsored by Tufts Medical Center.
NCT00868751 is a NA study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00868751, a NA study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA). Another purpose is to see if tocilizumab helps reduce the amount of steroids (prednisone) needed to control symptoms of soJIA.
Interventions
- BIOLOGICAL tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-06 |
| Phase | NA |
Why NCT00868751 stopped before completion
NCT00868751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which tocilizumab is the first listed.
NCT00868751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00868751 about?
NCT00868751 is a clinical study titled "Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis". The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA). Another purpose is to see if tocilizumab helps reduce the amount of steroids (prednisone) needed to control symptoms of soJIA.
What is the current status of trial NCT00868751?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2009-03. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00868751?
The interventions under investigation include: tocilizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00868751?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00868751's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia